iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Shares Shorted: Short Interest Down 55.2% in September

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 23,081 shares, a decrease of 55.2% from the August 31st total of 51,524 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 151,159 shares, the days-to-cover ratio is presently 0.2 days.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

A hedge fund recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Anchor Investment Management LLC acquired a new stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,898 shares of the company’s stock, valued at approximately $98,000.

iShares Genomics Immunology and Healthcare ETF Stock Up 2.0%

iShares Genomics Immunology and Healthcare ETF stock traded up $0.84 during mid-day trading on Tuesday, hitting $42.63. The company’s stock had a trading volume of 518,601 shares, compared to its average volume of 61,327. The stock’s fifty day moving average price is $37.51 and its two-hundred day moving average price is $32.89. The stock has a market capitalization of $292.02 million, a P/E ratio of 14.76 and a beta of 0.95. iShares Genomics Immunology and Healthcare ETF has a twelve month low of $23.10 and a twelve month high of $42.72.

iShares Genomics Immunology and Healthcare ETF Company Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.